Telmisartan Tab Hypertension - Full Text View

Sponsor:	Boehringer Ingelheim Pharmaceuticals
Information provided by:	Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00890084

Purpose

To assess the efficacy of telmisartan in hypertensive patients with high cardiovascular risk

Condition	Intervention
Hypertension	Drug: Telmisartan

Study Type:	Observational
Study Design:	Prospective
Official Title:	RESPECT: Observational, Prospective, Open-label, Multi-center Study Evaluating the Antihypertensive Effect of Treatment With Telmisartan (Alone or in Fixed Combination With HCTZ) in General Practitioner and Specialist Practice in Hypertensive Patients With High and Very High Cardiovascular Risk According to the ESH/ESC Guidelines 2007 Who Are Uncontrolled Under Current Treatment.

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Telmisartan

U.S. FDA Resources

Further study details as provided by Boehringer Ingelheim Pharmaceuticals:

Primary Outcome Measures:

To assess the overall effect of AHT with telmisartan after approx. 12 wks in GP and SP in uncontrolled hypertensive pnts with high and very high CV risk according ESH/ESC Guidelines 2007. [ Time Frame: approximately 3 months ]

Secondary Outcome Measures:

Identify baseline factors, patterns of concomitant medication that can help predict effect of AHT with Telmisartan after approx. 12 weeks. Identify types prescribers who accept/or not deliberate deviation from target BP. [ Time Frame: approximately 3 months ]

Enrollment:	16
Study Start Date:	April 2009
Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Detailed Description:

Study Design:

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

community sample

Criteria

Inclusion Criteria:

- Hypertensive patients with BP. 140/90mmHgand high and very high cardiovascular risk according to the ESH/ESC Guidelines 2007 and in whom the prescriber has taken the decision to start treatment with telmisartan 40 or 80 mg, with or without HCTZ 12.5 mg or 25 mg, in the usual way and in line with the SmPC and reimbursement criteria

Exclusion Criteria:

- Contra-indications as in the Summary of Product Characteristics

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00890084

Show 572 Study Locations

Sponsors and Collaborators

Boehringer Ingelheim Pharmaceuticals

Investigators

Study Chair:

Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals

More Information

No publications provided

Responsible Party:	Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair )
Study ID Numbers:	502.581
Study First Received:	April 28, 2009
Last Updated:	January 13, 2010
ClinicalTrials.gov Identifier:	NCT00890084 History of Changes
Health Authority:	Belgium: Federal Agency for Medicinal and Health Products

Additional relevant MeSH terms:

Angiotensin II Type 1 Receptor Blockers
Molecular Mechanisms of Pharmacological Action
Vascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Enzyme Inhibitors

Cardiovascular Diseases
Telmisartan
Pharmacologic Actions
Protease Inhibitors
Hypertension

ClinicalTrials.gov processed this record on February 08, 2010